COL18A1 and systemic sclerosis: Patients with systemic sclerosis had increased serum syndecan‐1 [223] and endostatin levels [224] as well as higher levels of serum biglycan fragments derived from MMP9/MMP12 activity at an early stage compared to the late stage of the disease [225].